| |
Apply advanced AI/ML methodologies to improve equity through data-informed site selection. Learn how to meet your enrollment diversity goals in this new insight brief — Download now. 
|
|
|
Wednesday, November 6, 2024 | 1pm ET / 10am PT Generative AI models help scientists better understand proteins, small molecules, DNA, biomedical text, and more. But building, training, and deploying these models can be complex. Join us to discuss the benefits of moving to the cloud to accelerate drug discovery pipelines, and why using customized AI models can help you get to market faster. Register now. 
|
|
| By Gabrielle Masson Last year, biotech shutdowns spiked. Thankfully, 2024’s numbers are a little lower, dropping from the 27 closures in 2023 to 22 this year. |
|
|
|
By Eric Sagonowsky Following a report of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation." |
By Nick Paul Taylor Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years. |
By Nick Paul Taylor AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The buyout will give AbbVie control of an Alzheimer’s disease drug candidate that Aliada in-licensed from Johnson & Johnson to try to improve on the first generation of anti-amyloid-beta antibodies. |
|
Thursday, November 7, 2024 | 11am ET / 8am PT This webinar will delve into how the next wave of AI—Agentic AI—has the potential to transform the R&D and development value chain, creating tangible business value. We will explore real-world applications and strategic approaches that solve pressing industry challenges, focusing on boosting productivity and profitability. Register now. 
|
|
By Kevin Dunleavy Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out. |
By Conor Hale Since rolling out its pulsed field ablation system for treating atrial fibrillation earlier this year, Boston Scientific has seen its Farapulse sales grow by leaps and bounds. |
By Darren Incorvaia Yet another CRO giant has taken a revenue hit due to a customer demand dip. Icon reported third-quarter revenue of $2.03 billion, underperforming analyst expectations of $2.142 billion. |
By Angus Liu To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the British drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. |
By Nick Paul Taylor The fog has lifted to reveal a rebranded biotech: Parabilis Medicines. Formerly called FogPharma, the biotech picked its new name to reflect its focus on expanding what is possible in the treatment of serious diseases and commitment to ensuring its medicines reach patients globally. |
By Joseph Keenan MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding production capacity at its antibody-drug conjugate facility in St. Louis. |
By Darren Incorvaia The National Science Foundation has awarded $615,000 to the laboratory of chemist Doug Frantz, Ph.D., at the University of Texas at San Antonio (UTSA), for a partnership with BMS that seeks to make pharma manufacturing more environmentally friendly. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Direct-To-Patient Cash Solutions for Pharma Manufacturers – learn how to leverage cash models strategically to mitigate access challenges and overcome the hurdles faced in today’s retail pharmacy environment. Sponsored by: KnippeRx |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
Survey Explore the latest trends in compliance monitoring to help your team embrace proactive strategies in key areas of risk management. Stay ahead of the ever-evolving landscape and new policies to enhance your compliance program. Sponsored by: IQVIA |
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Cognizant, in partnership with Microsoft, have interviewed 200 medtech decision makers across the UK, Ireland, France, Germany and the USA to find out about what the future holds. A responsible AI framework is going to be key. Read our report to learn more. Sponsored by: Cognizant and Microsoft |
Whitepaper Open up unexpected opportunities. This digital story offers pharma marketers proactive strategies for helping patients discover and switch to treatments, even if they aren’t actively looking to make a change. Sponsored by: Healthline Media |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
